Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

被引：56

作者：

Young, Wendy B. ^{[1
]}

Barbosa, James ^{[2
]}

Blomgren, Peter ^{[2
]}

Bremer, Meire C. ^{[1
]}

Crawford, James J. ^{[1
]}

Dambach, Donna ^{[1
]}

Gallion, Steve

Hymowitz, Sarah G. ^{[1
]}

Kropf, Jeffrey E. ^{[2
]}

Lee, Seung H. ^{[2
]}

Liu, Lichuan ^{[1
]}

Lubach, Joseph W. ^{[1
]}

Macaluso, Jen ^{[2
]}

Maciejewski, Pat ^{[2
]}

Maurer, Brigitte ^{[1
]}

Mitchell, Scott A. ^{[2
]}

Ortwine, Daniel F. ^{[1
]}

Di Paolo, Julie ^{[2
]}

Reif, Karin ^{[1
]}

Scheerens, Heleen ^{[1
]}

Schmitt, Aaron ^{[2
]}

Sowell, C. Gregory ^{[1
]}

Wang, Xiaojing ^{[1
]}

Wong, Harvey ^{[1
]}

Xiong, Jin-Ming ^{[2
]}

Xu, Jianjun ^{[2
]}

Zhao, Zhongdong ^{[2
]}

Currie, Kevin S. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Gilead Sci Inc, Branford, CT 06405 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 06期

关键词：

Kinase inhibitor; Bruton's tyrosine kinase; Btk; Rheumatoid arthritis; GDC-0834; Amide hydrolysis; Single dose IND; COLLAGEN-INDUCED ARTHRITIS; B-CELL; INFLAMMATORY DISEASES; IBRUTINIB;

D O I：

10.1016/j.bmcl.2015.01.032

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but with much improved PK in preclinical animal models. Structure based design efforts drove this work as modifications to 1 were investigated at both the solvent exposed region as well as 'H3 binding pocket'. However, in vitro metabolic evaluation of 2 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclinical species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics. Due to its promising potency, selectivity, and preclinical efficacy, a single dose IND was filed and 2 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics. In human, 2 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure. This information informed the back-up program and discovery of improved inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1333 / 1337

页数：5

共 50 条

[31] Bruton's Tyrosine Kinase Inhibitors: Recent Updates [J].

Fares, Amneh ;

Uribe, Carlos Carracedo ;

Martinez, Diana ;

Rehman, Tauseef ;

Rondon, Carlos Silva ;

Sandoval-Sus, Jose .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)

[32] Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors [J].

Pineda-Gayoso, Ricardo ;

Alomar, Mohammed ;

Lee, Dae Hyun ;

Fradley, Michael G. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)

[33] Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors [J].

Ricardo Pineda-Gayoso ;

Mohammed Alomar ;

Dae Hyun Lee ;

Michael G. Fradley .

Current Treatment Options in Oncology, 2020, 21

[34] Discovery of Reversible, Noncovalent Bruton's Tyrosine Kinase Inhibitors Targeting BTK C481S Mutation [J].

Das, Debasis ;

Xie, Lingzhi ;

Qiao, Dandan ;

Cao, Yuxi ;

Jiang, Shanling ;

Zheng, Mei ;

Liu, Zhonghe ;

Li, Yong ;

Jia, Jianhe ;

Lv, Yubin ;

Hong, Jian .

ACS MEDICINAL CHEMISTRY LETTERS, 2025, 16 (06) :1038-1047

[35] Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells [J].

Wang, Xianhui ;

Wong, Jason ;

Sevinsky, Christopher J. ;

Kokabee, Leila ;

Khan, Faiza ;

Sun, Yan ;

Conklin, Douglas S. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) :2198-2208

[36] Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors [J].

Wang, Jian ;

Ran, Ting ;

Chen, Yadong ;

Lu, Tao .

CHEMICAL BIOLOGY & DRUG DESIGN, 2020, 96 (04) :1113-1121

[37] Design and discovery of new selective and potent VEGF receptor 2 tyrosine kinase inhibitors [J].

Hou, Fei ;

Yao, Yuhong ;

Wei, Yujiao ;

Wang, Yubo ;

Cao, Yangzi ;

Liu, Xinqiang ;

Zheng, Liting ;

Zhang, Qingqing ;

Jiao, Yue ;

Chen, Yukun ;

Meng, Yue ;

Sun, Yue ;

Wu, Yanjie ;

Wang, Jiefu ;

Wang, Junfeng ;

Wu, Zhou ;

Zhang, Kun ;

Wei, Mingming ;

Yang, Guang .

BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 91

[38] Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma [J].

Varma, Gaurav ;

Johnson, Tyler P. ;

Advani, Ranjana H. .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (07) :543-554

[39] Selective Inhibition of Bruton?s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors [J].

Sousa, Barbara B. ;

De Almeida, Catia Rebelo ;

Barahona, Ana F. ;

Lopes, Raquel ;

Martins-Logrado, Ana ;

Cavaco, Marco ;

Neves, Vera ;

Carvalho, Luis A. R. ;

Labao-Almeida, Carlos ;

Coelho, Ana R. ;

Bento, Marta Leal ;

Lopes, Ricardo M. R. M. ;

Oliveira, Bruno L. ;

Castanho, Miguel A. R. B. ;

Neumeister, Peter ;

Deutsch, Alexander ;

Vladimer, Gregory I. ;

Krall, Nikolaus ;

Joao, Cristina ;

Corzana, Francisco ;

Seixas, Joao D. ;

Fior, Rita ;

Bernardes, Goncalo J. L. .

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (11) :1156-1168

[40] Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases [J].

Ma, Bin ;

Bohnert, Tonika ;

Otipoby, Kevin L. ;

Tien, Eric ;

Arefayene, Million ;

Bai, Judy ;

Bajrami, Bekim ;

Bame, Eris ;

Chan, Timothy R. ;

Humora, Michael ;

MacPhee, J. Michael ;

Marcotte, Douglas ;

Mehta, Devangi ;

Metrick, Claire M. ;

Moniz, George ;

Polack, Evelyne ;

Poreci, Urjana ;

Prefontaine, Annick ;

Sheikh, Sarah ;

Schroeder, Patricia ;

Smirnakis, Karen ;

Zhang, Lei ;

Zheng, Fengmei ;

Hopkins, Brian T. .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (21) :12526-12541

← 1 2 3 4 5 →